Improved outcomes of palliative radiotherapy combined with immune checkpoint inhibitors in recurrent or metastatic cervical cancers
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.113268 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xinyu Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local, Palliative Care. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Immunotherapy provides a remarkable survival advantage for patients with recurrent or metastatic cervical cancer (R/M CC). However, the role of immunotherapy in combination with radiotherapy in R/M CC remains unclear. METHODS: We retrospectively analyzed factors affecting immunotherapy effectiveness in patients with R/M CC. Clinical outcomes including tumor response and patient survival were assessed. Kaplan-Meier curves with the log-rank test were employed to compare survival data. Cox regression analysis was utilized to investigate prognostic factors. RESULTS: A total of 65 R/M CC patients treated with immune checkpoint inhibitors were eligible for analysis. We found that immunotherapy combined with palliative radiotherapy showed a significant positive correlation with complete response (OR = 6.31; 95 %CI: 1.74-22.91; p = 0.005). The 36-month progression-free survival (PFS) rate (73.7 % vs 33.8 %, p = 0.0048) and 36-month overall survival (OS) rate (85.7 % vs 38.7 %, p = 0.0043) were also prominently increased. We further demonstrated that patients prolonged 36-month PFS rate (69.9 % vs 15.2 %; p < 0.001) and 36-month OS rate (64.6 % vs 39.7 %; p = 0.032) when they had more than 4 cycles of immunotherapy. Meanwhile, our findings showed that patients with only recurrence had longer 36-month OS rate (77.7 % vs 44.4 % vs 40.1 %; p = 0.024) compared to those with only metastasis and both. We also observed that patients with squamous carcinoma had higher 2-year PFS rate (57.9 % vs 14.6 %; p = 0.042) than those with other pathological subtypes (adenocarcinoma, adenosquamous carcinoma and neuroendocrine carcinoma). CONCLUSIONS: The combination of immunotherapy and palliative radiotherapy increased complete response rates and improved survivals in recurrent or metastatic cervical cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
- Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Hubei Key Laboratory of Tumor Biological Behavior, Zhongnan Hospital of Wuhan University, Wuhan 430071, China; Hu…
Zitieren
APA
Pan, X., Guo, X., Wang, J., Yang, C., Chen, M., Qiu, H., & Wu, Q. (2024). Improved outcomes of palliative radiotherapy combined with immune checkpoint inhibitors in recurrent or metastatic cervical cancers. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.113268
Vancouver
Pan X, Guo X, Wang J, Yang C, Chen M, Qiu H, et al. Improved outcomes of palliative radiotherapy combined with immune checkpoint inhibitors in recurrent or metastatic cervical cancers. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.113268
BibTeX
@article{Pan2024,
author = {Pan, Xinyu and Guo, Xiaowan and Wang, Juan and Yang, Chunxu and Chen, Min and Qiu, Hui and Wu, Qiuji},
title = {Improved outcomes of palliative radiotherapy combined with immune checkpoint inhibitors in recurrent or metastatic cervical cancers},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.113268}
}
EUVIMED